• 中
    • Pipeline

    Pipeline

    MicuRx is dedicated to creating treatments for patients with infections caused by multidrug-resistant super bacteria. Beyond that, MicuRx also has a pipeline of other investigational medicines for cancer and inflammation.

    • Contezolid (MRX-I) MRX-I

      1、Next generation oxazolidinone antibiotic designed and developed by MicuRx
      2、Target multidrug-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus,vancomycin-resistant Enterococci, penicillin-resistant Streptococcus pneumoniae, etc
      3、Supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during 11th, 12th, 13th five-year period

      4、Global Multi-Center Phase III trial initiated (MRX-4 sequential Contezolid)

      • Patent filled in 2008
      • China IND approved in 2010
      • QIDP and Fast Track granted by US FDA by 2018
      • China Phase 3 trial completed in 2019
      • NDA granted priority review by NMPA in 2020
      • NDA approved by NMPA in 2021

    • MRX-4 MRX-4

      1、Injectable new oxazolidinone antibiotics designed and developed by MicuRx
      2、Target multidrug-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus,vancomycin-resistant Enterococci, penicillin-resistant Streptococcus pneumoniae, etc
      3、Supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during 13th five-year period

      4、Global Multi-Center Phase III trial initiated (MRX-4 sequential Contezolid)

      • Patent filled in 2015
      • US Phase 1 trial completed in 2017
      • QIDP and Fast Track granted by US FDA by 2018
      • US Phase 2 trial completed in 2019
      • China Phase 1 trial completed in 2021
      • China Phase 3 trial completed in 2024

    • MRX-8 MRX-8

      1、Next generation polymyxin antibiotic designed and developed by MicuRx
      2、Target multidrug-resistant Gram-negative bacteria, including carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Klebsiella pneumoniae, etc
      3、Supported by National Major Scientific and Technological Special Project for “Significant New Drugs Development” during 13th five-year period

      • Patent filled in 2015
      • US IND approved in 2020
      • US Phase I trail completed in 2022
      • Chinese Phase I trail completed in 2024

    • MRX-5 MRX-5

      1、Novel boron compound designed and developed by MicuRx
      2、Target non-tuberculous Mycobacteria infection

      • Australian Phase I trail completed in 2024

    • MRX-17 MRX-17

      1、Novel kidney-targeted treatment designed and developed by MicuRx
      2、To achieve superior efficacy and safety by increasing the local concentration of active drug via renal-targeted delivery

    • MRX-23 MRX-23

      A next-generation monoclonal antibody drug conjugate (ADC) targeting tumors

      Featuring a new generation of camptothecin toxin and an optimized linker

    • MRX-15 MRX-15

      1、Novel kidney-targeted treatment designed and developed by MicuRx
      2、To achieve superior efficacy and safety by increasing the local concentration of drug via renal-targeted delivery